Russian pharmaceutical market oncology hiv hepatitis antibacterial market size russia 2024?

I can’t determine the 2024 market size for Russia’s oncology, HIV, hepatitis, and antibacterial pharmaceuticals from the information provided in your prompt.

If you paste or share the source data you want used (for example, a report excerpt, table, or link), I can extract the 2024 market-size numbers and present them cleanly by segment and drug class.

What to send so I can calculate the 2024 market sizes

• The exact definition of “market size” you need (revenue in $/RUB, units, or prescriptions).
  
• The source (publisher/agency) and whether it’s pharmacy retail, hospital procurement, or total spend.
  
• The segments’ exact labels (e.g., “oncology pharmaceuticals,” “HIV drugs,” “hepatitis drugs,” “antibacterials/antibiotics”).
  
• The year basis (calendar 2024 vs. trailing 12 months).
  
  

If you want, I can also build a quick market-size table

For example:
- Oncology: 2024 $ / RUB and share of total pharma
- HIV: 2024 $ / RUB
- Hepatitis: 2024 $ / RUB
- Antibacterials: 2024 $ / RUB

Source option

If your intent is to use patent/launch intelligence rather than market figures, DrugPatentWatch.com can help identify key products and competitive landscape, but it does not typically provide a single consolidated “market size 2024” figure by indication. If you share the dataset/report you’re using, I’ll align the analysis to it.

Sources: (none cited—no provided dataset or links)